Trudhesa® nTRx Increased by 27% in Q3 2022 vs. Q2 2022 to 16.7k: Net Product Revenue Increased to $3.1 Million…
Third quarter 2022 revenue of $41.7 million, bringing year to date revenue to $78.8 million.Core life science revenue of $20.5…
- MDNA11’s selectivity and dose-dependent stimulation of anti-cancer immune cells indicates potential for increased anti-tumor activity with continued dose escalation…
Biomarker results are a positive demonstration of target engagement for this first-in-class CBL-B inhibitor Biomarker levels achieved with NX-1607 treatment correspond…
New data shows that CAR T cells engineered in vivo with VivoVec particles mediate durable antitumor activity Potent and durable…
Presentations highlight use of Nurix’s first-in-class CBL-B inhibitor NX-0255 to enhance growth and profile of T cells for cell therapy…
TPST-1120 Late-breaking Poster Presentation at SITC Annual MeetingSecond Poster Presentation Demonstrates that Dual Blockade of EP2 and EP4 PGE2 Receptors…
-- Median overall survival (OS) for patients with metastatic, microsatellite stable colorectal cancer (MSS-CRC) who had two prior lines of…
Successful combination of technologies will expand the opportunities for IMUNON’s DNA-based modality and broaden applications for the PLACCINE nucleic acid…
Topline data anticipated in early 2023NEW ORLEANS and LONDON, Nov. 09, 2022 (GLOBE NEWSWIRE) -- Revolo Biotherapeutics (“Revolo” or the…